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Stereocontrolled	Semi-Syntheses	of	Deguelin	and	Tephrosin†		
David	A.	Russell,a	Julien	J.	Freudenreich,a		Joe	J.	Ciardiello,a	Hannah	F.	Sorea	and	David	R.	Spring*a	
We	describe	stereocontrolled	semi-syntheses	of	deguelin	and	tephrosin,	anti-cancer	rotenoids	isolated	from	Tephrosia	
vogelii.	Firstly,	we	present	a	new	two-step	transformation	of	rotenone	into	rot-2’-enonic	acid	via	a	zinc-mediated	ring	
opening	of	rotenone	hydrobromide.	Secondly,	following	conversion	of	rot-2’enonic	acid	into	deguelin,	a	chromium-
mediated	hydroxylation	provides	tephrosin	as	a	single	diastereoisomer.	An	Étard-like	reaction	mechanism	is	proposed	to	
account	for	the	stereochemical	outcome.	Our	syntheses	of	deguelin	and	tephrosin	are	operationally	simple,	scalable	and	
high	yielding,	offering	considerable	advantages	over	previous	methods.	
Introduction	
Natural	rotenoids	display	a	wide	range	of	biological	activities,	from	
strong	 pesticidal	 and	 insecticidal	 activities	 to	 therapeutically	
intriguing	 anticancer	 properties.1,2	 Deguelin	 1	 and	 tephrosin	 2	
(Figure	 1)	 were	 isolated	 from	 Teprosia	 vegelii	 by	 Hanriot	 in	 1907	
and	immediately	identified	as	the	principal	bioactive	components	of	
the	 plant.3	 Clark	 subsequently	 deduced	 the	 skeletal	 structures	 of	
both	 substances	 between	 1930	 and	 19324	 and	 their	 absolute	
stereochemistries	were	resolved	by	analogy	with	rotenone	in	1961	
through	Crombie’s	inspired	degradative	work5	and	Djerassi’s	optical	
rotatory	dispersion	studies.6			
Over	 the	 past	 two	 decades	 deguelin	 1,	 in	 particular,	 has	 been	
shown	 to	 inhibit	 the	 viability,	 proliferation	 and	 migration	 of	
multiple	 cancer	 cell	 lines,2	 including	 difficult	 to	 treat	 prostate	
cancer2i	 and	 pancreatic	 cancers	 xenograft	 models.2j	 Further,	
rationally	 designed	 analogues	 of	 deguelin	 1	 have	 been	 shown	 to	
disrupt	 the	 function	of	HSP-90,	 leading	 to	 inhibition	of	HIF-1α	and	
induction	 of	 mitochondrial	 apoptosis.7	 As	 such,	 the	 synthesis	 and	
biological	 evaluation	of	 rotenoids	 remains	an	area	of	 considerable	
interest	and	opportunity.	
As	 part	 of	 an	 extensive	 series	 of	 studies	 on	 the	 rotenoid	 group	
underway	 in	 our	 laboratory	 we	 required	 gram-scale	 quantities	 of	
deguelin	 1	 and	 tephrosin	 2.	 While	 several	 impressive	 total	
syntheses	 of	 both	 natural	 products	 have	 been	 reported,8	 we	
reasoned	 that	 shorter	 stereocontrolled	 semi-syntheses	 from	
rotenone	3,	available	commercially	in	kilogram	quantities,	would	be	
better	suited	to	large-scale	preparations.				
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A	 semi-synthesis	 of	 deguelin	 1	 from	 rotenone	 3	 	 (Figure	 1)	 was	
reported	by	Anzeveno	in	1979,9	building	upon	Unai,	Yamamoto	and	
Crombie’s	 earlier	 works	 on	 the	 selective	 E-ring	 cleavage	 of	
rotenone.10,11	 The	 key	 intermediate	 in	 the	 synthesis	 was	 rot-2’-
enonic	 acid	 5	 (Scheme	 1),	 however	 its	 preparation	 involved	 the	
reductive	 dehalogenation	 of	 an	 allylic	 bromide	 with	 sodium	
cyanoborohydride	in	neat	hexamethylphosphoramide.9		
Consequently,	we	sought	a	new	route	to	rot-2’-enonic	acid	5	using	
less	 hazardous	 chemistry	 that	 could	 be	 more	 easily	 scaled-up	 to	
provide	 gram	 quantities	 of	 deguelin	 1	 following	 Anzeveno’s	
cyclisation	 of	 rot-2’-enonic	 acid	 5.9	 On	 the	 basis	 of	 Crombie’s	
studies	 on	 the	 diastereoselective	 chromium-mediated	
hydroxylation	of	rotenone	3	to	rotenolone	4,5b	we	reasoned	that	an	
analogous	hydroxylation	of	 deguelin	1	with	potassium	dichromate	
in	aqueous	acetic	acid	would	provide	tephrosin	2.	
	
Figure	 1:	 Structures	 of	 the	 rotenoids	 deguelin	1,	 tephrosin	2,	 rotenone	3	
and	rotenolone	4	and	rot-2’-enonic	acid	5.	
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Results	and	discussion	
First,	 we	 addressed	 the	 synthesis	 of	 rot-2’-enonic	 acid	 5,	 the	
synthetic	 and	 biosynthetic	 precursor	 to	 deguelin	 1,	 starting	 from	
rotenone	3.	A	new	two-step	synthesis	was	devised	in	which	a	zinc-
mediated	ring	opening	of	rotenone	hydrobromide	6	afforded	rot-2’-
enonic	acid	5	under	mild	conditions	(Scheme	1).			
The	 reaction	 of	 rotenone	 3	 with	 hydrogen	 bromide	 in	 acetic	 acid	
afforded	 rotenone	 hydrobromide	 6	 in	 82-89%	 yield	 following	 its	
precipitation	 from	 the	 reaction	 mixture	 and	 crystallisation	 from	
chloroform-methanol.	 Best	 results	 were	 obtained	 with	 fresh	
reagent.	 Further,	 the	 reaction	 of	 rotenone	 hydrobromide	 6	 with	
excess	activated	zinc	dust	and	ammonium	chloride	in	aqueous	THF	
proceeded	smoothly	to	provide	rot-2’-enonic	acid	5	in	74-79%	yield	
after	 extraction	 and	 crystallisation	 from	 methanol.	 Complete	
conversion	of	starting	material	was	observed	after	2	days.	The	use	
of	 commercial	 (un-activated)	 zinc	 dust	 afforded	 comparable	
conversion	and	yield	after	4	days.	 In	 addition,	 the	 coagulated	 zinc	
that	 formed	 over	 the	 course	 of	 the	 reaction	 may	 be	 recovered	
(prior	to	extractive	work-up)	and	reused.	 	We	were	able	to	rapidly	
prepare	 more	 than	 2.5	 g	 of	 rot-2’-enonic	 acid	 5	 from	 4	 g	
(approximately	 10	 mmol)	 of	 rotenone	 3	 without	 the	 need	 for	
chromatography.	
Having	established	a	scalable	route	to	rot-2’-enonic	acid	5,	and	with	
multiple	 grams	 of	 material	 in	 hand,	 we	 sought	 to	 complete	 the	
syntheses	of	deguelin	1	and	tephrosin	2.	Treatment	of	rot-2’-enonic	
acid	 5	 with	 phenylselenyl	 chloride	 in	 dichloromethane	 at	 -35	 oC,	
according	 to	 Anzeveno’s	 established	 procedure,9	 afforded	 an	
approximately	1:1	mixture	of	5’-epimeric	selenides	7	in	quantitative	
yield.	 The	 crude	 selenides	 7	 were	 immediately	 oxidised	 with	
hydrogen	 peroxide	 in	 aqueous	 THF	 at	 0	 oC	 to	 their	 corresponding	
selenoxides	 8,	 which	 underwent	 spontaneous	 elimination	 upon	
warming	 to	 room	 temperature	 to	 afford	 deguelin	 1	 in	 81%	 yield	
from	rot-2’-enonic	acid	5.		
Lastly,	we	were	pleased	to	observe	that	the	reaction	of	deguelin	1	
with	 potassium	 dichromate	 in	 aqueous	 acetic	 acid	 proceeded	
smoothly	to	afford	tephrosin	2	in	76%	yield.	
A	 mechanism	 for	 the	 dichromate	 hydroxylation	 of	 deguelin	 1	 is	
proposed	 in	 which	 we	 view	 the	 transformation	 as	 an	 Étard-like	
benzylic	 oxidation.12	 Oxidation	 of	 an	 enol	 intermediate	 is	
discounted	on	the	basis	of	the	Crombie	and	Unai’s	extensive	studies	
on	 the	 aerial	 oxidation	 of	 enolates	 derived	 from	natural	 (optically	
active)	 and	 racemic	 rotenoids,	 which	 afford	 diastereoisomeric	
mixtures	of	cis	and	trans	alpha-hydroxylated	products.5b,13			
In	 accordance	 with	 the	 Étard-like	 mechanism,12b	 a	 necessarily	
diastereoselective	(facially	selective)	ene	reaction	between	deguelin	
1	and	the	oxidant	affords	a	stereodefined	organochromium	species	
9	 that	 subsequently	 undergoes	 a	 [2,3]-sigmatropic	 rearrangement	
to	 form	 a	 tertiary	 chromate	 ester	 10.	 Hydrolysis	 of	 the	 chromate	
ester	 upon	 work-up	 then	 affords	 tephrosin	 2	 as	 a	 single	
diastereoisomer.	 We	 would	 therefore	 attribute	 the	
diastereoselective	outcome	of	 the	 reaction	 to	 its	 doubly	pericyclic	
nature,	 the	 necessary	 geometric	 requirements	 of	 these	 processes	
together	with	the	characteristic	‘butterfly-wing’	architecture	of	the	
starting	material.		
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Scheme	 1:	 Reagents	 and	 conditions:	 a)	 HBr,	 AcOH,	 rt,	 0.5	 h,	 87%;	 b)	 Zn,	
NH4Cl,	THF,	H2O,	rt,	48	h,	79	%;	c)	PhSeCl,	CH2Cl2,	-40	
oC,	2	h	then	rt,	1	h;	d)	
aq	H2O2,	THF,	0	
oC,	1h,	then	rt,	18	h,	81%	from	5;	e)	K2Cr2O7,	AcOH,	H2O,	60	
oC,	0.5	h	then	rt,	18	h,	76%.	
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Conclusions	
We	 have	 developed	 stereocontrolled	 semi-syntheses	 of	 both	
deguelin	1	and	tephrosin	2	starting	from	rotenone	3	and	proceeding	
via	rot-2’-enonic	acid	5.	Firstly,	a	new	transformation	of	rotenone	3	
into	rot-2’-enonic	acid	5	 is	described	that	 involves	a	zinc-mediated	
ring	 opening	 of	 rotenone	 hydrobromide	 6.	 This	 alternative	
preparation	of	rot-2’-enonic	acid	5	avoids	the	use	of	the	highly	toxic	
reagents	previously	required	in	Anzeveno’s	synthesis9	and	affords	a	
higher	 yield	 across	 two	 steps	 (approximately	 70%	 vs	 35%).	 The	
conversion	 of	 rot-2’-enonic	 acid	 5	 into	 deguelin	 1	 was	 achieved	
following	 Anzeveno’s	 method.9	 Finally,	 the	 transformation	 of	
deguelin	 1	 into	 tephrosin	 2	 was	 accomplished	 using	 a	 highly	
diastereoselective	chromium-mediated	hydroxylation,	for	which	an	
Étard-like	 reaction	 mechanism	 is	 tentatively	 proposed.12b	 Our	
syntheses	provide	deguelin	1	and	tephrosin	2	in	56%	and	42%	yield	
respectively,	 involve	 only	 two	 chromatographic	 purifications	 and	
allow	 gram	 quantities	 of	 valuable	 enantiopure	 materials	 to	 be	
prepared	 simply	 and	 efficiently,	 facilitating	 biological	 studies	
thereof.	
Lastly,	we	note	that	although	commercially	available	at	the	time	of	
writing,	 deguelin	1	 and	 tephrosin	2	 cost	 approximately	 2x104	 and	
2x105	 times	 more	 than	 rotenone	 3.	 We	 present	 operationally	
simple	 semi-syntheses	 of	 deguelin	1	 and	 tephosin	2	 starting	 from	
relatively	inexpensive	rotenone	3	using	similarly	low-cost	reagents.	
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